Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03707080 · ClinicalTrials.gov registry record
Direct Acting Antiviral-Post Authorization Safety Study
A clinical trial, sponsored by Target PharmaSolutions.
- Completed
- Registry status
- 42
- Enrollment target
NCT03707080: Completed study, sponsored by Target PharmaSolutions.
NCT03707080 is a clinical trial that has completed, run by Target PharmaSolutions. The registered enrollment target is 42 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03707080 has completed, sponsored by Target PharmaSolutions.
- COMPLETED
- Registry status
- 42 participants
- Enrollment target
Study Summary
This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting antivirals (DAAs) on early recurrence of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-infected patients following successful HCC treatment interventions.
Primary Outcome
Time to HCC recurrence associated with DAA therapy relative to no DAA therapy in the prospective cohort.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2018-03-09 |
| Est. Completion | 2021-06-30 |
What the finished NCT03707080 record still lists
NCT03707080 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 42 participants, a relatively small participant target.
The record links to 0 conditions, and to 0 interventions.
NCT03707080 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03707080 about?
NCT03707080 is a clinical study titled "Direct Acting Antiviral-Post Authorization Safety Study". This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting antivirals (DAAs) on early recurrence of hepatocellular carcinoma (HCC) in hepat...
What is the current status of trial NCT03707080?
This trial is currently completed. The enrollment target is 42 participants. The study started on 2018-03-09. Estimated completion is 2021-06-30.
Who is sponsoring clinical trial NCT03707080?
This trial is sponsored by Target PharmaSolutions, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02852213 · 42 participants · Phase 1
A Single-Stage, Adaptive, Open-label, Dose Escalation Safety and Efficacy Study of AADC Deficiency in Pediatric Patients
- NCT03136146 · 42 participants · Phase 2
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia
- NCT03178149 · 42 participants · Phase 1
A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
- NCT03663530 · 42 participants · NA
Circadian Misalignment and Energy Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI